Indefinite Delivery Contract 75N93021D00006

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products addressing HIV, HBV, HCV, and Mycobacterium tuberculosis. Valued at up to $107 million over seven years, the contracts authorize task orders across seven areas including in vitro testing, synthesis of therapeutic agents, small animal models, formulation development, pharmacology/toxicology studies, and a reagent program.

Two sample task orders were issued to the University of Nebraska Medical Center under the Preclinical Services for HIV Therapeutics master contract. One task order, valued at $13,328.86, is for development of a quality assurance plan and participation in a kickoff meeting to support HIV/AIDS research. The other funds the minimum contract amount through June 2021.

The original solicitation sought proposals for the seven task areas, with Task Area B for small-scale synthesis set aside for small businesses. Services include screening and testing of therapeutics, developing and refining animal models of HIV, HBV, HCV and Mycobacterium, formulation and manufacturing of clinical supplies, and preclinical assessment of safety and efficacy. The overall aim is to provide resources to advance promising candidates from basic research through clinical evaluation.